Correction to: COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study

Węcławek-Tompol, Jadwiga; Zakrzewska, Zuzanna; Gryniewicz–Kwiatkowska, Olga; Pierlejewski, Filip; Bień, Ewa; Zaucha‐Prażmo, Agnieszka; Zając‐Spychała, Olga; Szmydki‐Baran, Anna; Mizia‐Malarz, Agnieszka; Bal, Wioletta; Sawicka-Żukowska, Małgorzata; Kruk, Agnieszka; Ociepa, Tomasz; Raciborska, Anna; Książek, Agnieszka; Szczepański, Tomasz; Peregud-Pogorzelski, Jarosław; Krawczuk‐Rybak, Maryna; Chaber, Radosław; Matysiak, Michał; Wachowiak, Jacek; Irga‐Jaworska, Ninela; Młynarski, Wojciech; Dembowska‐Bagińska, Bożenna; Balwierz, Walentyna; Matkowska-Kocjan, Agnieszka; Kazanowska, Bernarda; Styczyński, Jan; Ussowicz, Marek

doi:10.1186/s13045-022-01279-3

Cited by 3 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The withdrawal or delay of cancer treatment, after COVID-19 infection, has been the practice of many pediatric cancer centers during the pandemic. 10,[13][14][15]18,26,27 Our results add to emerging evidence that the continuance of cancer-directed therapy is safe, particularly for those who are asymptomatic or with mild symptoms. 16,20,33,42,43 The long-term impact of treatment delays incurred due to the COVID-19 pandemic is not yet known.…”

Section: Discussionmentioning

confidence: 55%

“…Also, population vaccination rates increased, substantially limiting severe infections 28,32–34 . These developments evolved over time and could have impacted pediatric oncology patients 6,8–15,27,28,32–34 . As such, we might expect outcomes from studies considering COVID-19 infection early in the pandemic to be comparable and outcomes from later studies, while differing from early data, to be comparable with those from the same time period.…”

Section: Discussionmentioning

confidence: 99%

“…28,[32][33][34] These developments evolved over time and could have impacted pediatric oncology patients. 6,[8][9][10][11][12][13][14][15]27,28,[32][33][34] As such, we might expect outcomes from studies considering COVID-19 infection early in the pandemic to be comparable and outcomes from later studies, while differing from early data, to be comparable with those from the same time period. Support for this outcome variability explanation is weakened, as data emergent from similar time periods has not been consistent.…”

Section: Discussionmentioning

confidence: 99%

“…7,[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] COVID-19 infection has also resulted in the delay or withdrawal of cancer-directed therapy. 7,[13][14][15][16][17]26,27 To date, data for Canadian childhood cancer patients with COVID-19 have not been reported apart from 4 pediatric centers in Quebec. 15 The primary objectives of this study were to describe patient characteristics at the time of COVID-19 infection and outcomes of infection; including interruptions to cancer therapy, hospitalization, and associated mortality, in children with cancer treated at 12 Canadian pediatric oncology centers between January 2020 and December 2021.…”

mentioning

confidence: 99%

“…Significant heterogeneity in COVID-19 outcomes for children with cancer has been observed; hospitalization rates, an imperfect surrogate marker of moderate-severe infection, range from 5% to 68.1%, intensive care unit (ICU) admissions from 0% to 25%, and mortality from 0% to 4.3% 7,9–26 . COVID-19 infection has also resulted in the delay or withdrawal of cancer-directed therapy 7,13–17,26,27 …”

mentioning

confidence: 99%

See 4 more Smart Citations

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Mark

Gibson

Lafay‐Cousin

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Published outcomes for children with cancer with coronavirus disease 2019 (COVID-19) have varied. Outcome data for pediatric oncology patients in Canada, outside of Quebec, have not been reported. This retrospective study captured patient, disease, and COVID-19-related infectious episode characteristics and outcome data for children, 0 to 18 years, diagnosed with a first COVID-19 infection between January 2020 to December 2021 at 12 Canadian pediatric oncology centers. A systematic review of pediatric oncology COVID-19 cases in high-income countries was also undertaken. Eighty-six children were eligible for study inclusion. Thirty-six (41.9%) were hospitalized within 4 weeks of COVID-19; only 10 (11.6%) had hospitalization attributed to the virus, with 8 being for febrile neutropenia. Two patients required intensive care unit admission within 30 days of COVID-19 infection, neither for COVID-19 management. There were no deaths attributed to the virus. Of those scheduled to receive cancer-directed therapy, within 2 weeks of COVID-19, 20 (29.4%) experienced treatment delays. Sixteen studies were included in the systematic review with highly variable outcomes identified. Our findings compared favorably with other high-income country's pediatric oncology studies. No serious outcomes, intensive care unit admissions, or deaths, in our cohort, were directly attributable to COVID-19. These findings support the minimization of chemotherapy interruption after COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Mark

Gibson

Lafay‐Cousin

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

Safety of Sotrovimab use in children with COVID-19: an Italian experience

Venturini,

Fusani,

Lo Vecchio

et al. 2023

Journal of Chemotherapy

View full text Add to dashboard Cite

One-year follow-up of children hospitalized with COVID-19: a prospective cohort study

Jacoby Schmidt1,

Morin Casassola2,

Hoff Affeldt1

et al. 2023

J Bras Pneumol.

View full text Add to dashboard Cite

Objective: Currently, little is known about the long-term outcomes of COVID-19 in the pediatric population. The aim of this study was to investigate the long-term clinical outcomes of pediatric patients hospitalized with COVID-19. Methods: This was a prospective cohort study involving unvaccinated children and adolescents admitted to a tertiary hospital in southern Brazil with a COVID-19 diagnosis. Data were collected from electronic medical records for one year after the diagnosis. Results: A total of 66 children were included: the median age was 2.9 years; 63.6% were male; and 48.5% were under 2 years of age. Over 70% had at least one comorbidity prior to the COVID-19 diagnosis. During the one-year follow-up period, 59.1% of the children revisited the emergency department, 50% required readmission, and 15.2% died. Younger children with longer hospital stays were found to be at greater risk of readmission. Having cancer and impaired functionality were found to increase the risk of death within one year. Conclusions: Our findings indicate that most children hospitalized with COVID-19 have comorbidities. Younger age at admission and a longer hospital stay seem to be risk factors for readmission. In addition, the presence of cancer and impaired functionality are apparently associated with the poor outcome of death within the first year after the diagnosis of COVID-19.

show abstract

Correction to: COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study

Cited by 3 publications

References 1 publication

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Safety of Sotrovimab use in children with COVID-19: an Italian experience

One-year follow-up of children hospitalized with COVID-19: a prospective cohort study

Contact Info

Product

Resources

About